Completed PHASE2 INTERVENTIONAL NCT00427050

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

An Open-label, Multi-centre, Dose-escalation, Cohort Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel When Applied to a 25 cm2 Contiguous Actinic Keratoses Treatment Area on the Face or Face and Scalp.

Sponsor: Peplin

Conditions Actinic Keratoses

Interventions PEP005

Updated 5 times since 2017 Last updated: Sep 11, 2015 Started: Jan 31, 2007 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Actinic Keratoses and is currently completed. Peplin leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peplin

Data source: Peplin

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Belmont Specialist Centre, 1202 Creek Rd, Carina Heights, Australia
• Benowa, Australia
• Brisbane, Australia
• Darlinghurst, Australia
• Epsom, New Zealand
• Hamilton, New Zealand
• Kogarah, Australia
• Level 3, 22 Belgrave St, Kogarah, Australia
• Tauranga, New Zealand